Last update 21 Nov 2024
Timdarpacept
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Fusion protein |
Synonyms Recombinant human signal regulating protein alpha (SIRPalpha) fragment crystallizable (Fc)-fusion protein (ImmuneOnco) + [1] |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Login to view timeline
Gene Sequence
Sequence Code 942330967
Source: *****
Related
11
Clinical Trials associated with TimdarpaceptA Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
注射用IMM01（替达派西普）联合替雷利珠单抗对比研究者选择的化疗方案治疗抗PD-(L)1单抗难治性经典型霍奇金淋巴瘤（cHL）受试者的随机、开放、对照、多中心III期临床研究
[Translation] A randomized, open-label, controlled, multicenter phase III clinical study of IMM01 (tiedapircept) for injection combined with tislelizumab versus chemotherapy selected by the investigator in the treatment of subjects with classical Hodgkin lymphoma (cHL) refractory to anti-PD-(L)1 monoclonal antibodies
A Phase III Randomized, Open-label, Multicenter Clinical Study of IMM01 (Timdarpacept) in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma
100 Clinical Results associated with Timdarpacept
Login to view more data
100 Translational Medicine associated with Timdarpacept
Login to view more data
100 Patents (Medical) associated with Timdarpacept
Login to view more data
100 Deals associated with Timdarpacept
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Myelomonocytic Leukemia | Phase 3 | CN | 24 Oct 2024 | |
| Classical Hodgkin's Lymphoma | Phase 3 | - | 01 Jun 2024 | |
| Refractory Classic Hodgkin Lymphoma | Phase 3 | - | 01 Jun 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 10 May 2022 | |
| Acute Myeloid Leukemia | Preclinical | CN | 18 Oct 2021 | |
| Extranodal NK-T-Cell Lymphoma | Preclinical | CN | 18 Oct 2021 | |
| Multiple Myeloma | Preclinical | CN | 18 Oct 2021 | |
| Recurrent Myelodysplastic Syndrome | Preclinical | CN | 18 Oct 2021 | |
| Refractory Myelodysplastic Syndrome | Preclinical | CN | 18 Oct 2021 | |
| Refractory Lymphoma | Discovery | CN | 09 Sep 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05833984 (ESMO2024) Manual  | Phase 2 | 33 | (rfezheysya) = wqevnucdll xqdlaxidjs (lqfilkyjuv ) View more | Positive | 15 Sep 2024 | ||
NCT05140811 (ESMO2024) Manual | Phase 2 | Chronic Myelomonocytic Leukemia First line | 22 | (gbpnewjver) = dubprpmzoz jpchogaxjc (qyxeabsrzc ) View more | Positive | 13 Sep 2024 | |
Phase 2 | 57 | rhhvvhiurn(oxuliopsau) = only 1.8% axazvgbdyg (fkdoimxvxu ) View more | Positive | 24 May 2024 | |||
Phase 2 | High Risk Myelodysplastic Syndrome First line | 54 | (qgpekrzewn) = leukopenia (81.5%), thrombocytopenia (68.5%), neutropenia (66.7%), lymphopenia (57.4%), anemia (44.4%) and infection(16.7%) zsxksdpjbm (pwvhamscrp ) View more | - | 09 Dec 2023 | ||
Phase 2 | Chronic Myelomonocytic Leukemia First line | 24 | (gnuethdovd) = 25.0% nxoguqirrx (rsfspospiz ) View more | - | 09 Dec 2023 | ||
CTR20220791 (ASCO2023) Manual | Phase 1/2 | 14 | (vrunqvikks) = ejxchfroos caakcujumn (ykqbehxzim ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free